Adaptive Biotechnologies
1551 Eastlake Ave E
Suite 200
Seattle
Washington
98102
United States
133 articles with Adaptive Biotechnologies
-
New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern
6/9/2021
Adaptive’s immunoSEQ T-MAP COVID provides potential explanation for preservation of Johnson & Johnson vaccine (Ad26.COV2.S) response to variants even when neutralizing antibodies are diminished
-
Adaptive Biotechnologies Reports First Quarter 2021 Financial Results
5/5/2021
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2021.
-
Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference
4/27/2021
Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will be participating in the upcoming BofA Securities 2021 Virtual Healthcare Conference.
-
Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference
2/25/2021
Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will be participating in the upcoming Cowen 41st Annual Healthcare Conference.
-
Q2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution
12/21/2020
Q 2 Solutions, an IQVIA and Quest Diagnostics Joint Venture, Teams With Adaptive Biotechnologies to Market immunoSEQ® Assay, the Leading Quantitative Large-Scale Immunosequencing Solution MORRISVILLE, N.C.--( BUSINESS WIRE )-- Q 2 Solutions, a leading global clinical trial laboratory services organization, resulting from an IQVIA and Quest Diagnostics joint venture, today announced a partnership with Adaptive Biotechnologies, a pioneer and leader in im
-
Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting
12/6/2020
MRD assessment with clonoSEQ improves outcomes both for patients and the healthcare system, as patients with undetectable MRD may be able to discontinue active treatment
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 12, 2020.
-
Adaptive Biotechnologies and Microsoft launch groundbreaking ImmuneCODE database to share populationwide immune response to the COVID-19 virus
6/11/2020
Decoding the immune response to the virus from thousands of patient samples may contribute to the development of novel diagnostics, vaccines and therapeutics Data will be updated regularly and made freely available to researchers and public health officials around the world
-
UPDATE – Adaptive Biotechnologies to Participate in Upcoming June 2020 Investor Conferences
6/8/2020
This release was previously disseminated on May 27, 2020 at 16:03 ET. The date and time details for the conferences have been updated.
-
Adaptive Biotechnologies Reports First Quarter 2020 Financial Results
5/12/2020
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the quarter ended March 31, 2020.
-
Clinical Catch-Up: May 4-8
5/11/2020
It’s the first time in several weeks that the number of non-COVID-19-related clinical trial stories outnumber the COVID-19-related stories. It’s also a hopeful sign that some of the rest of the clinical trials are getting back on track. Here’s a look. -
Adaptive Biotechnologies to Report First Quarter Financial Results on May 12, 2020
4/27/2020
Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced it will report financial results for the first quarter 2020 after market close on Tuesday, May 12, 2020.
-
Adaptive Biotechnologies Expands Executive Leadership Team to Support Development and Commercialization of Clinical Products, including immunoSEQ Dx
4/9/2020
Adaptive Biotechnologies, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the addition of two prominent hires to its executive leadership team.
-
Amgen And Adaptive Biotechnologies Announce Strategic Partnership To Develop A Therapeutic To Prevent Or Treat COVID-19
4/2/2020
Adaptive Extends Immune Medicine Platform to Discover Therapeutic Antibodies From Recovered COVID-19 Patients Amgen Will Leverage Genetics, Immunology, Antibody Engineering and Manufacturing Capabilities Companies Will Begin Work Immediately
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 2, 2020.
-
Adaptive Biotechnologies and Microsoft expand partnership to decode COVID-19 immune response and provide open data access
3/20/2020
Adaptive Biotechnologies Corp. (Nasdaq: ADPT) and Microsoft Corp. (Nasdaq: MSFT) on Friday announced they will leverage their existing partnership mapping population-wide adaptive immune responses to diseases at scale to study COVID-19.
-
Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2019 Financial Results
2/26/2020
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, reported financial results for the fourth quarter and full year ended December 31, 2019.
-
Adaptive Biotechnologies to Present at the 40th Annual Cowen Health Care Conference
2/19/2020
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced the company will be participating in the upcoming 40th Annual Cowen Health Care Conference in Boston, MA.
-
Adaptive Announces Pricing of Public Offering of Common Stock at $26.50 per share
1/24/2020
Adaptive Biotechnologies Corporation, a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, announced today the pricing of its underwritten public offering of 8,000,000 shares of its common stock by certain selling shareholders at a public offering price of $26.50 per share, before underwriting discounts and commissions.